Antibodies that bind human interleukin-18 and methods of making and using
CA 2800450 A1 · Owner: Abbvie Inc. · Inventors: Roguska, Mike; Duncan, Alexander Robert; Labkovsky, Boris
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Antibodies that bind human interleukin-18 (hIL-18) are provided in particular , antibodies that , bind epitope(s) of human IL-18. The antibodies can be for example, entirely , human , antibodies recombinant antibodies, or monoclonal antibodies. Perferred antibodies have , high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of , the invention can be a full-length antibody or an antigen-binding protion thereof. Method of , making and method of using the antibodies of the invention are also provided. The , Antibodies, or antibody portions of the invention are useful for detecting hIL- 18 and for , inhibiting hIL-18 activity e.g. in a human subject …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 9, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 9, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 9, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.